Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody
Trial ID or NCT#
Status
Purpose
The purpose of this study is to assess the safety and tolerability of Hu5F9-G4 in participants with solid tumors.
Official Title
A First-in-Human Phase 1 Dose Escalation Trial of Hu5F9-G4 in Patients With Advanced Solid Malignancies
Eligibility Criteria
- Patients with histologically or cytologically confirmed advanced solid malignancy or Lymphoma Relapsed or refractory disease after at least 1 prior systemic treatment for the primary malignancy and not a candidate for other curative treatment. Adequate hematologic status Adequate coagulation function Adequate hepatic function Adequate renal function
- Known primary tumors of central nervous system disease Known active brain metastases Known cardiopulmonary disease
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
CCTO
1-650-498-7061
View on ClinicalTrials.gov